Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Upgrade: Dedicated Screeners for Stocks & ETFs

Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?

By Zacks Equity Research | July 23, 2025, 9:57 AM

Vertex Pharmaceuticals Inc

Zai Lab Limited ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Vertex Pharmaceuticals Inc

Zai Lab Limited ADR

Latest News

Oct-28	Zai Lab's Rally Meets A Test: Can Sequential Sales Gains Hold As Cash Burn Persists? ZLAB Earnings Whispers
Oct-27	BofA Names this Drugmaker a Top Pick on Promising Kidney Drug Data VRTX Investing.com
Oct-26	Vertex Heads Into Q3 With Raised Guidance As Casgevi And Gernavix Ramps Face Proof Test VRTX Earnings Whispers
Oct-23	Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026 VRTX Business Wire
Oct-23	How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs VRTX Investor's Business Daily
Oct-22	Zai Lab Announces $250 Million Private Placement ZLAB -8.93% Business Wire
Oct-21	7 healthcare stocks that stand out as investors pay up for the sector VRTX MarketWatch
Oct-21	Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026 ZLAB Business Wire
Oct-20	Vertex Appoints Daniel Brennan to its Board of Directors VRTX Business Wire
Oct-14	Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31R Bispecific Antibody, for Atopic Diseases ZLAB Business Wire
Oct-13	Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors VRTX MarketWatch
Oct-09	Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis Conference VRTX Business Wire
Oct-09	Is Vertex Stock Worth More Than Its Competitors? VRTX Trefis
Oct-08	Pacira BioSciences Stock Surges 44% on $1.7 Billion Viatris Acquisition VRTX Barrons.com
Oct-07	Vertex to Announce Third Quarter 2026 Financial Results November 2nd VRTX Business Wire

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)